Back to top

gene-therapy: Archive

Zacks Equity Research

REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study

Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.

SRPTNegative Net Change ADMAPositive Net Change RGNXNegative Net Change SLDBPositive Net Change

Zacks Equity Research

Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.

RHHBYPositive Net Change ACETNegative Net Change SRPTNegative Net Change PBYIPositive Net Change

Zacks Equity Research

Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up

Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.

VRTXPositive Net Change ACETNegative Net Change EDITNegative Net Change AKRONegative Net Change

Zacks Equity Research

BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales

BioMarin (BMRN) reports encouraging fourth-quarter results, with earnings and sales beating estimates. The rapid uptake of Voxzogo boosts revenues.

SNYPositive Net Change BMRNNegative Net Change ACETNegative Net Change PBYIPositive Net Change